Skip Navigation


Schizophrenia Bulletin Advance Access originally published online on August 28, 2007
Schizophrenia Bulletin 2007 33(6):1277-1283; doi:10.1093/schbul/sbm096
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
33/6/1277    most recent
sbm096v2
sbm096v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Deutch, A. Y.
Right arrow Articles by Bubser, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Deutch, A. Y.
Right arrow Articles by Bubser, M.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2007. Published by Oxford University Press on behalf of the Maryland Psychiatric Research Center. All rights reserved. For permissions, please email: journals.permissions@oxfordjournals.org.

The Orexins/Hypocretins and Schizophrenia

Ariel Y. Deutch1 and Michael Bubser
Departments of Psychiatry and Pharmacology, Vanderbilt University Medical Center, Nashville, TN 37212

1 To whom correspondence should be addressed; Psychiatric Hospital at Vanderbilt, Suite 313, 1601 23rd Avenue South, Nashville, TN 37212; tel: 615-327-7080, fax: 615-322-1901, e-mail: ariel.deutch{at}vanderbilt.edu.

Advances in molecular biology have led to new peptides and proteins being discovered on a regular basis, including the isolation of a number of neurotransmitter candidates. Rarely, however, do these immediately capture the attention of the scientific community. The isolation and characterization of the orexin/hypocretin peptides a decade ago resulted in a slew of studies that have helped clarified their diverse functions, including prominent roles in arousal and appetitive behavior. A number of recent studies have detailed the role of the orexins/hypocretins in attention and cognition and uncovered an involvement in schizophrenia and the mechanisms of action of antipsychotic drugs (APDs). This issue of Schizophrenia Bulletin presents several articles that review our current understanding and point to future directions for the study of the orexins/hypocretins in schizophrenia and APD actions.

Keywords: dopamine / cognition / antipsychotic drugs


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Schizophr BullHome page
D. Dickinson and P. D. Harvey
Systemic Hypotheses for Generalized Cognitive Deficits in Schizophrenia: A New Take on An Old Problem
Schizophr Bull, August 9, 2008; (2008) sbn097v1.
[Abstract] [Full Text] [PDF]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.